Opendata, web and dolomites

H2020MM04 SIGNED

DC-based immunotherapy to treat Malignant Mesothelioma

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 H2020MM04 project word cloud

Explore the words cloud of the H2020MM04 project. It provides you a very rough idea of what is the project "H2020MM04" about.

prospects    adverse    environment    prolonged    treat    autologous    granted    cells    approval    millions    banned    poor    cell    scientific    06    health    fatal    chemotherapy    combination    despite    first    fibres    signs    tremendously    immunotherapy    ema    erasmus    exposed    inhalation    tumour    2065    fda    workers    resolution    clinical    2012    resistant    16    orphan    deaths    12    designation    2010    iarc    24    occupational    13    1229    pulmonary    netherlands    standard    survival    allogeneic    disease    therapy    time    union    extensive    asbestos    abolishing    threats    treatment    extremely    lysate    death    2014    consisting    therapeutic    carcinogens    illness    market    ini    pulsed    trial    actions    pemetrexed    dendritic    massively    median    protecting    malignant    mm    aggressive    considerably    personalised    treatments    incidence    date    consumers    quantities    rotterdam    registration    limited    reported    risk    curative    care    months    mc    cisplatin    history    mesothelioma    last    immuno    diseases    events    january    twice    international   

Project "H2020MM04" data sheet

The following table provides information about the project.

Coordinator
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM 

Organization address
address: DR MOLEWATERPLEIN 40
city: ROTTERDAM
postcode: 3015 GD
website: www.erasmusmc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website https://www.denimstudy.eu/
 Total cost 5˙782˙965 €
 EC max contribution 5˙782˙965 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-PHC-2015-two-stage
 Funding Scheme RIA
 Starting year 2016
 Duration (year-month-day) from 2016-01-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) coordinator 2˙375˙146.00
2    UNIVERSITA POLITECNICA DELLE MARCHE IT (ANCONA) participant 669˙452.00
3    STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS NL (AMSTERDAM) participant 669˙451.00
4    UNIVERSITY OF LEICESTER UK (LEICESTER) participant 669˙215.00
5    UNIVERSITAIR ZIEKENHUIS ANTWERPEN BE (EDEGEM) participant 668˙874.00
6    CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE FR (LILLE) participant 659˙822.00
7    AMPHERA BV NL (DEN BOSCH) participant 48˙000.00
8    EUROPEAN CANCER PATIENT COALITION BE (BRUXELLES) participant 23˙000.00

Map

 Project objective

Asbestos is one of the major occupational carcinogens. The European Union has an extensive history of protecting workers and consumers against asbestos and even adopted a resolution 2012/2065(INI) ‘on asbestos related occupational health threats and prospects for abolishing all existing asbestos’ last year. Although asbestos is banned, it is still massively present in the built environment. Millions of workers & consumers in the EU were, and still are, for many years exposed to asbestos fibres, despite all measures.

Inhalation of even very low quantities of asbestos fibres tremendously increases the risk of developing Malignant Mesothelioma (MM). The IARC reported 8.100 MM deaths in 2010 in the EU. Despite all EU actions, MM incidence is still increasing. MM is a highly fatal disease with a poor median survival time from first signs of illness to death around 12 months despite aggressive treatments. To date there is no curative therapy for MM. MM is considered as an extremely therapy-resistant disease. Chemotherapy consisting of a combination of pemetrexed and cisplatin is considered standard of care with a median survival increase of 3 months (9-12 months).

The department of pulmonary diseases of the Erasmus MC, Rotterdam, The Netherlands, in collaboration with international partners, have developed a promising personalised immunotherapy for MM with very limited adverse effects. The first clinical results show a considerably prolonged average survival with limited adverse events (24 months, twice as long).

The EMA and the FDA granted this therapy Orphan Designation: autologous dendritic cells pulsed with allogeneic tumour cell lysate for the treatment of malignant mesothelioma (EU: 16 January 2014 - EU/3/13/1229; FDA – US: 06 May 2014).

The objective for the project is to deliver the scientific & registration package for market approval by the EMA of a novel immuno therapeutic approach to treat MM. This includes the execution of a phase II/III clinical trial.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "H2020MM04" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "H2020MM04" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

Read More